Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Atrial fibrillation: diagnosis and management (NG196)
Generalised anxiety disorder and panic disorder in adults: management (CG113)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 25 studies.
Reviews & meta-analyses: 3 · 1980–2025
Showing all 25 studies, sorted by most relevant.
A Cherubini, A Djuv, A Fugh-Berman, et al.
Drugs & Aging, 2017
- Age Factors
- Phytotherapy
- Plant Preparations
BACKGROUND: The use of herbal medicinal products (HMPs) is common among older adults; however, little is known about concurrent use with prescription drugs, as well as potential interactions associated with such combinations. OBJECTIVE: The aim of this systematic review was to identify and evaluate the literature on concurrent prescription and HMP use among older adults to assess prevalence, patterns, potential interactions and factors associated with this use. METHODS: Systematic searches were conducted in the MEDLINE, PsycINFO, EMBASE, CINAHL, AMED, Web of Science and Cochrane databases from inception to May 2017 for studies reporting concurrent use of prescription medicines with HMPs in adults ≥ 65 years of age. Quality was assessed using the Joanna Briggs Institute checklists. And the Evidence for Policy and Practice Information and Co-ordinating Centre (EPPI-Centre) three-stage approach to mixed method research was used to synthesise data. RESULTS: Twenty-two studies were included. A definition of HMPs or what was considered an HMP was frequently missing. Prevalence of concurrent use by older adults varied widely between 5.3 and 88.3%. Prescription medicines most combined with HMPs were antihypertensive drugs, β-blockers, diuretics, antihyperlipidemic agents, anticoagulants, analgesics, antihistamines, antidiabetics, antidepressants and statins. The HMPs most frequently used were Ginkgo biloba, garlic, ginseng, St John's wort, Echinacea, saw palmetto, evening primrose oil and ginger. Potential risks of bleeding due to the use of Ginkgo biloba, garlic or ginseng with aspirin or warfarin was the most reported herb-drug interaction. Some data suggest being female, and having a lower household income and less than a high-school education were associated with concurrent use. CONCLUSION: The prevalence of concurrent prescription drugs and HMP use among older adults is substantial and potential interactions have been reported. Knowledge of the extent and manner in which older adults combine prescription drugs will aid healthcare professionals in appropriately identifying and managing patients at risk. Systematic Review Registration Number: PROSPERO 2014:CRD42014009091.
Abstract licence: CC BY-NC
Haiyang Xu, Jinghua Wang, Mingxian Li, et al.
Journal of Headache and Pain, 2016
- Anti-Inflammatory Agents, Non-Steroidal
- Ibuprofen
- Migraine Disorders
BACKGROUND: Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans. METHODS: We conducted systematic searches in database PubMed and Embase. Treatment effectiveness was compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area (SUCRA) was created to rank those interventions. RESULTS: Eletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan. CONCLUSION: This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.
Abstract licence: CC BY
M. Sebaiy, S. El-Adl, Amr A. Mattar
The Gazette of Medical Sciences, 2020
Parvateesam Yenda, N. K. Katari, Santhosh Kumar Ettaboina, et al.
Biomedical chromatography : BMC, 2023
- Acetaminophen
- Caffeine
- Aspirin
Ayman Ismail, M. Gamal, M. Nasr
Pharmaceutical Chemistry Journal, 2023
A. Ezzati, K. Fanning, Michael L. Reed, et al.
Headache: The Journal of Head and Face Pain, 2023
- Acetaminophen
- Migraine Disorders
- Anti-Inflammatory Agents, Non-Steroidal
Sobhy M. El-adl, Amr A. Mattar, Omar M El-Abassy, et al.
BMC Chemistry, 2025
A UV-chemometric approach has been developed to analyze a ternary combination of aspirin, caffeine, and orphenadrine citrate without the need for previous separation. The method is easy, specific, accurate, and highly precise. The three medications were evaluated simultaneously utilizing CLS, PLS, and PCR, which were generated based on separate data sets that yielded superior findings. Regrettably, their accurate estimation could only be achieved using the PLS approach. In order to determine the prediction power of each chemometric approach, its validity has been tested using 8 synthetic mixes. The latent variable number varies across various models as the dataset changes. The comparison of various methodologies and the assessment of the predictive capacity of each set of data were done using the predicted residual error sum of squares (PRESS) and the root mean square error of prediction (RMSEP). The created approach was also used to statistically compare the performance of PLS in a dataset with zero absorption, as well as to compare the performance of the offered chemometric methods in various datasets. The environmental impact of the created approach was assessed to determine the overall ecological sustainability of the designed methodology. According to the new Blue Applicability Grade Index (BAGI) evaluation methodology, the suggested technique was also found to be practicable.
Abstract licence: CC BY
Hareesh Divadari Hareesh Divadari, Teja Kamireddy Teja Kamireddy, Rama Krishna Mynen Rama Krishna Mynen, et al.
International Journal of Pharmaceutical Research and Applications, 2024
E. Dichi, M. Sghaier, N. Guiblin
Journal of Thermal Analysis and Calorimetry, 2023
Ahmed Mahdi Saeed, Omer Jasim Mohammed, Nada Ghaaeb Hussein
Research Journal of Pharmacy and Technology, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.